Vanda Pharmaceuticals Inc. 8-K Filing
Ticker: VNDA · Form: 8-K · Filed: Nov 28, 2025 · CIK: 1347178
| Field | Detail |
|---|---|
| Company | Vanda Pharmaceuticals Inc. (VNDA) |
| Form Type | 8-K |
| Filed Date | Nov 28, 2025 |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Vanda Pharmaceuticals Inc. (ticker: VNDA) to the SEC on Nov 28, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.001 (ich registered Common Stock, par value $0.001 per share VNDA The Nasdaq Global Market).
How long is this filing?
Vanda Pharmaceuticals Inc.'s 8-K filing is 1 pages with approximately 443 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 443 words · 2 min read · ~1 pages · Grade level 10.3 · Accepted 2025-11-28 07:06:24
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share VNDA The Nasdaq Global Market
Filing Documents
- vnda-20251128.htm (8-K) — 29KB
- vnda8-k11282025exhibit991.htm (EX-99.1) — 11KB
- vandaq32019earningsca_imag.jpg (GRAPHIC) — 48KB
- 0001628280-25-054225.txt ( ) — 228KB
- vnda-20251128.xsd (EX-101.SCH) — 2KB
- vnda-20251128_lab.xml (EX-101.LAB) — 22KB
- vnda-20251128_pre.xml (EX-101.PRE) — 13KB
- vnda-20251128_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events. On November 28, 2025, Vanda Pharmaceuticals Inc. ("Vanda") issued a press release providing a regulatory update on Vanda's drug, tradipitant, for the treatment of motion sickness. The full text of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release of Vanda Pharmaceuticals Inc. dated November 28, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: November 28, 2025 VANDA PHARMACEUTICALS INC. By: /s/ Timothy Williams Name: Timothy Williams Title: Senior Vice President, General Counsel and Secretary